Fibroblast Technology Developed for Diabetic Foot Ulcers and Chronic Wounds
FibroBiologics, in collaboration with Charles River, has announced the completion of a master cell bank for a novel fibroblast-based therapy aimed at treating chronic wounds, including diabetic foot ulcers (DFUs). The product, designated CYWC628, utilizes a spheroid approach to deliver fibroblast cells topically, promoting wound healing by releasing essential growth factors and cytokines.
According to Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics, “Fibroblasts are involved in every single stage of the wound healing process.” He notes that chronic wounds like DFUs often fail to heal due to cellular senescence, and this new therapy aims to address that by rejuvenating the wound environment.
CYWC628 has passed all required safety testing, and clinical trials are scheduled to commence in the second quarter of 2025. The 12-week study will evaluate the product’s efficacy in promoting healing in patients with chronic wounds.
Read the full article on the Healio website.
Keywords:
Fibroblast therapy,
Chronic wounds,
Diabetic foot ulcers,
CYWC628,
Wound healing,
Cell-based therapy,
Growth factors,
Clinical trials,
Cellular senescence